Samsung Biologics Q2 Net Profit Increases 29.1% Driven by Operational Efficiency and FX Tailwinds

Samsung Biologics reported a 29.1% year-on-year increase in Q2 net profit, attributed to sustained full-capacity utilization of its manufacturing plants and favorable currency exchange rates. The results reflect continued demand for contract development and manufacturing organization (CDMO) services, though the sustainability of these margins remains contingent on global biotech funding cycles.